stockrow
Saturday 7 November 2026
Export EIKN’s income statement to Excel — free account
Eikon Therapeutics, Inc.
EIKN Healthcare Biotechnology
5.92
0.08
+1.37%
Follow EIKN
Alert me
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+2 more quarters Free account |
— | 6.34 | 11.75 | 9.89 |
Net Debt/EBITDA |
0.00 | 0.00 | 6.23 | 6.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.31 | 0.00 | 1.08 | 0.73 | |
Capex/Depreciation |
(3.44) | (1.93) | (0.05) | (0.05) | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(19.12) | 0.00 | (2.67) | (1.20) | |
Cash per Share |
0.00 | 0.00 | 15.21 | 9.82 | |
Shareholders Equity per Share |
0.00 | 0.00 | 16.34 | 8.62 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 16.34 | 8.62 | |
Free Cash Flow |
(54.45) | (235.26) | (90.06) | (65.21) | |
Working Capital |
— | 293.91 | 484.44 | 491.68 | |
Capital Expenditures |
(21.72) | (46.74) | (0.26) | (0.25) | |
Net Current Asset Value |
0.00 | (1,124.85) | 229.35 | 233.91 | |
| Other line items | |||||
Quick Ratio |
— | 6.12 | 11.37 | 9.61 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(11.49) | 0.00 | (2.66) | (1.20) | |
Capex per Share |
(7.62) | 0.00 | (0.01) | 0.00 | |
Average Assets |
— | — | 671.03 | 389.79 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026